Evidence map›Paper›PMID 27133344›Full record

SynthesisIndian heart journal

Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention.

Sadegh Ali-Hassan-Sayegh, Seyed Jalil Mirhosseini, Azadeh Shahidzadeh, Parisa Mahdavi, Mahbube Tahernejad, Fatemeh Haddad, Mohammad Reza Lotfaliani, Anton Sabashnikov, Aron-Frederik Popov

Erratum issuedOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Precision percutaneous coronary intervention.NPJ cardiovascular health · 2026
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sadegh Ali-Hassan-SayeghCardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Electronic address: S.alihassan.cardiosurg@gmail.com.
Seyed Jalil MirhosseiniCardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Azadeh ShahidzadehCardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Parisa MahdaviCardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Mahbube TahernejadCardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Fatemeh HaddadCardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Mohammad Reza LotfalianiCardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Anton SabashnikovDepartment of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
Aron-Frederik PopovDepartment of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
Shahid Sadoughi University of Medical Sciences and Health Services · IRRoyal Brompton & Harefield NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This systematic review with meta-analysis sought to determine the efficacy and safety of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) on clinical outcomes following percutaneous coronary intervention. Medline, Embase, Elsevier, and web of knowledge as well as Google scholar literature were used for selecting appropriate studies with randomized controlled design. After screening 445 studies, a total of 23 trials (including a total of 43,912 patients) were identified that reported outcomes. Pooled analysis revealed that LMWH compared to UFH could significantly increase thrombolysis in myocardial infarction grade 3 flow (p<0.001), which was associated with similar target vessel revascularization (p=0.6), similar incidence of stroke (p=0.7), and significantly lower incidence of re-myocardial infarction (p<0.001), major bleeding (p=0.02) and mortality (p<0.001). Overall, LMWH was shown to be a useful type of heparin for patients with MI undergoing PCI, due to its higher efficacy and lower rate of complication compared to UFH. It is also associated with increased myocardial perfusion, decreased major hemorrhage, and mortality.

Indexed as

AnticoagulantsHeparinHeparin, Low-Molecular-WeightHumansInjections, IntravenousIntraoperative ComplicationsIntraoperative PeriodMyocardial InfarctionTreatment OutcomeAnticoagulantsHeparinHeparin, Low-Molecular-WeightLow molecular weight heparinMyocardial infarctionOutcomePercutaneous coronary interventionUnfractionated heparin

Identifiers

PMID27133344
PMCPMC4867946
OpenAlexW2273668107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.